Adavosertib - AstraZeneca

Drug Profile

Adavosertib - AstraZeneca

Alternative Names: AZD 1775; L001739996-008U; MK-1775 hemihydrate; MK1775

Latest Information Update: 04 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Developer AstraZeneca; Canadian Cancer Trials Group; Cancer Research UK; Merck & Co; National Cancer Institute (USA); Samsung Medical Center; University of Birmingham; University of Washington
  • Class Antineoplastics; Piperazines; Pyrazoles; Pyrimidinones; Small molecules
  • Mechanism of Action WEE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer
  • Phase I/II Solid tumours
  • Phase I Colorectal cancer; Glioblastoma; Haematological disorders; Head and neck cancer; Uterine cancer; Vulvovaginal cancer
  • Preclinical Diffuse large B cell lymphoma
  • Discontinued Cervical cancer

Most Recent Events

  • 10 Jul 2018 MD Anderson Cancer Center, in collaboration with National Cancer Institute, plans a phase II trial for Ovarian cancer, Fallopian tube cancer, Peritoneal cancer (Combination therapy, Monotherapy, Metastatic disease, Recurrent, Second-line therapy or greater) in USA in September 2018 (NCT03579316)
  • 01 Jun 2018 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Solid tumours presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 21 Apr 2018 Preclinical trials in Diffuse large B cell lymphoma (Combination therapy) in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top